Open Access

Expression of Oct‑4 is significantly associated with the development and prognosis of colorectal cancer

  • Authors:
    • Huan Zhou
    • Yu Hu
    • Weipeng Wang
    • Yong Mao
    • Jingjie Zhu
    • Bin Zhou
    • Jing Sun
    • Xueguang Zhang
  • View Affiliations

  • Published online on: May 26, 2015     https://doi.org/10.3892/ol.2015.3269
  • Pages: 691-696
  • Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Octamer‑binding transcription factor 4 (Oct‑4), is an essential transcription factor, which is required for pluripotency and self‑renewal in embryonic stem cells and germ cells. It is also involved in maintaining cancer stem‑like properties in certain types of tumor, and is an important biomarker for cancer stem cells. The present study investigated whether Oct‑4 expression was associated with colorectal cancer (CRC). In order to achieve this, primary CRC tissues, matched non‑tumor tissues and benign polyp tissues, representing different stages of carcinogenesis, were obtained, and Oct‑4 expression was analyzed using reverse transcription‑quantitative polymerase chain reaction, flow cytometry analysis and immunohistochemistry. Furthermore, the medical records of patients with CRC were reviewed, and clinicopathological analysis was performed in order to assess the association between Oct‑4 expression and certain clinicopathological parameters. It was shown that the transcription and translation of Oct‑4 increased in a stepwise manner, from non‑tumor to benign polyp tissues, and from benign polyps to CRC tissues. Oct‑4 expression in CRC was significantly correlated with histological grade (P=0.007), lymph node metastasis (P=0.027), distant metastasis (P=0.017) and TNM stage (P=0.041). Kaplan‑Meier survival curve analysis demonstrated that Oct‑4+ cases had a shorter median survival time (37.0 months) compared with Oct‑4- cases (76.0 months; P=0.001). These results indicated that aberrant expression of Oct‑4 may be involved in the development of CRC. Thus, Oct‑4 may be a biomarker for the prediction, diagnosis or assessment of prognosis in CRC, in addition to a potential target for the treatment of this disease.
View Figures
View References

Related Articles

Journal Cover

August-2015
Volume 10 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhou H, Hu Y, Wang W, Mao Y, Zhu J, Zhou B, Sun J and Zhang X: Expression of Oct‑4 is significantly associated with the development and prognosis of colorectal cancer. Oncol Lett 10: 691-696, 2015
APA
Zhou, H., Hu, Y., Wang, W., Mao, Y., Zhu, J., Zhou, B. ... Zhang, X. (2015). Expression of Oct‑4 is significantly associated with the development and prognosis of colorectal cancer. Oncology Letters, 10, 691-696. https://doi.org/10.3892/ol.2015.3269
MLA
Zhou, H., Hu, Y., Wang, W., Mao, Y., Zhu, J., Zhou, B., Sun, J., Zhang, X."Expression of Oct‑4 is significantly associated with the development and prognosis of colorectal cancer". Oncology Letters 10.2 (2015): 691-696.
Chicago
Zhou, H., Hu, Y., Wang, W., Mao, Y., Zhu, J., Zhou, B., Sun, J., Zhang, X."Expression of Oct‑4 is significantly associated with the development and prognosis of colorectal cancer". Oncology Letters 10, no. 2 (2015): 691-696. https://doi.org/10.3892/ol.2015.3269